Therapeutic DNA vaccines against tuberculosis: A promising but arduous task

Chinese Medical Journal

Volumn 119, Issue 13, 2006, Pages 1103-1107

  Li, Jun Ming ^a   Zhu, Dao Yin ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

DNA vaccine; Therapy; Tuberculosis

Indexed keywords

BCG VACCINE; DNA VACCINE; TUBERCULOSTATIC AGENT;

ADJUVANT THERAPY; BACTERIAL IMMUNITY; BCG VACCINATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFORMATION PROCESSING; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM VACCAE; NONHUMAN; REVIEW; TH1 CELL; TH2 CELL; THERAPY RESISTANCE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

EID: 33746113303     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200607010-00008     Document Type: Review

References (32)

1. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet 2003; 362: 887-899.
2. MacMicking JD, Taylor GA, McKinney JD. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 2003; 302: 654-659.
3. Fine PE, Carneiro AMI, Milstien BJ. Issues relating to the use of BCG in immunization programmes: a discussion document. WHO Bull 1999; 23.
4. Reed S, Lobet Y. Tuberculosis vaccine development from mouse to man. Micro Infec 2005; 7: 922-931.
5. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001; 19: 93-129.
6. Girard MP, Fruth U, Kieny MP. A review of vaccine research and development: tuberculosis. Vaccine 2005; 23: 5725-5731.
7. Moreira AL, Tsenova L, Aman MH, Bekker LG, Freeman S, Mangaliso B, et al. Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice. Infect Immun 2002; 70:2100-2107.
8. Durban IG. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Lancet 1999; 354:116-119.
9. Tang D, Devit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356: 152-154.
10. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-1749.
11. Robinson HL, Hunt LA, Webster RG. Protection against lethal influenza virus challenge by immunization with a hemagglutininexpressing plasmid DNA. Vaccine 1993; 11: 957-960.
12. Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, Deck RR, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996; 2: 893-898.
13. Tascon RE, Colston MJ, Ragno S, Stavropoulos E, Gregory D, Lowrie DB. Vaccination against tuberculosis by DNA injection. Nat Med 1996; 2: 888-892.
14. Lowrie DB, Tascon RE, Bonato VLD, Lima VMF, Faccioli LH, Stavropoulos E, et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999; 400: 269-271.
15. Ha SJ, Jeon BY, Kim SC, Kim DJ, Song MK, Sung YC, et al. Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis. Gene Ther 2003; 10:1592-1599.
16. Turner J, Rhoades E, Keen M, Belisle JT, Frank AA, Orme IM. Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun 2000; 68:1706-1709.
17. Repique CJ, Li A, Collins FM, Morris SL. DNA immunization in a mouse model of latent tuberculosis: effect of dna vaccination on reactivation of disease and on reinfection with a secondary challenge. Infect Immun 2002; 70:3318-3323.
18. Taylor JL, Turner OC, Basaraba RJ, Belisle JT, Huygen K, Orme IM. Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect Immun 2003; 71: 2192-2198.
19. Silva CL, Bonato VL, Coelho-Castelo AA, De Souza AO, Santos SA, Lima KM, et al. Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice. Gene Therapy 2005; 12: 281-287.
20. Ha SJ, Jeon BY, Youn JI, Kim SC, Cho SN, Sung YC. Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis. Gene Therapy 2005; 12: 634-638.
21. Zhu DY, Jiang S, Luo, XD. Therapeutic effects of Ag85B and MPT64 DNA vaccines in a murine model of Mycobacterium tuberculosis infection. Vaccine 2005; 23: 4619-4624.
22. Rook GAW, Dheda K, Zumla A. Immune response to tuberculosis in develop countries: implications for new vaccine. Nat Rev Immun 2005; 5: 661-667.
23. Rook GAW, Hernandez-Pando R, Dheda K, Seah GT. IL-4 in tuberculosis: implications for vaccine design. Trends Immunol 2004; 25: 483-488.
24. Ashkar AA, Rosenthal KL. Toll-like receptor 9, CpG DNA and innate immunity. Curr Mol Med 2002; 2:545-556.
25. Hayashi M, Kuwahara M, Ogata M, Miyao-Kurosaki N, Abel T, Ueki R, et al. Evaluating the immune responses stimulated by CpG oligodeoxynucleotides. Nucleic Acids Res Suppl 2003;3:323-324.
26. Mitsuyama M, Akagawa K, Kobayashi K, Sugawara I, Kawakami K, Yamamoto S, et al. Up-to-date understanding of tuberculosis immunity. Kekkaku 2003; 78: 51-55.
27. Haile M, Kallenius G. Recent developments in tuberculosis vaccines. Curr Opin Infect Dis 2005; 18: 211-215.
28. Huygen K. Plasmid DNA vaccination. Microbes Infect 2005; 7: 932-938.
29. Orme IM. Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine 2006; 24: 2-19.
30. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-544.
31. Camus JC, Pryor MJ, Medigue C, Cole ST. Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 2002; 148: 2967-2973.
32. Lowe DB, Shearer MH, Kennedy RC. DNA vaccines: successes and limitations in cancer and infectious disease. J Cell Biochem 2006; 98:235-242.